Over a median 3.1-year follow-up, SGLT2 inhibitor use was associated with a 24% relative risk reduction in the composite of death or heart failure admission, with notably lower all-cause mortality and risk of sudden cardiac death (hazard ratio of 0.56 and 0.50, respectively). The gene discussed is SLC5A2; the disease is heart failure.